A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Inclusion Criteria

• •1. Patient has provided informed consent form (ICF).
• •2. Males or females aged ≥ 18 years.
• •3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1.
• •4. Life expectancy \> 3 months judged by the investigator.
• •5. Have histologically or cytologically confirmed advanced KRAS G12C-mutated NSCLC.
• •6. Have at least one measurable lesion per RECIST 1.1.
• •7. Have sufficient organ functions.
• •8. With toxicities left from prior anti-tumor therapy resolved to baseline or CTCAE Grade 1 (neurotoxicity or alopecia ≤ Grade 2).
• •9. Women of childbearing potential (WOCBP) and male patients with WOCBP partners must agree to use effective contraception method during the study specified period.